Aptus Capital Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Aptus Capital Advisors’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-286,543	Closed	-$24.8M	–	1817
2026 Q1	$24.8M	Buy	286,543 +286,455	+325,517%	+$25.1M	0.2%	96
2025 Q4	$7.46K	Buy	88 +1	+1%	+$80	﹤0.01%	1519
2025 Q3	$6.31K	Hold	87	–	–	﹤0.01%	1472
2025 Q2	$5.69K	Buy	87 +1	+1%	+$65	﹤0.01%	1409
2025 Q1	$6.09K	Hold	86	–	–	﹤0.01%	1323
2024 Q4	$5.67K	Hold	86	–	–	﹤0.01%	1326
2024 Q3	$6.07K	Sell	86 -183,349	-100%	-$12.8M	﹤0.01%	1133
2024 Q2	$12.2M	Buy	+183,435	New	+$12M	0.21%	96

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Aptus Capital Advisors's IHE Position: Q2 2026 in Review

Aptus Capital Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q2 2026, closing a stake of 286,543 shares — an estimated $24.8M sold.

Aptus Capital Advisors first reported a position in IHE in Q2 2024 and held it in 8 quarters. The position peaked at $24.8M in Q1 2026. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Aptus Capital Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
Aptus Capital Advisors sold 286,543 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $24.8M.
Aptus Capital Advisors first reported a position in iShares US Pharmaceuticals ETF in Q2 2024 and held it in 8 quarters.
Aptus Capital Advisors's iShares US Pharmaceuticals ETF position peaked at $24.8M in Q1 2026.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.